Mayo Clinic Physicians Present New Research on Heart Transplant Care and Long-term Outcomes
ROCHESTER, Minn. — Heart transplant experts from Mayo Clinic presented findings from three recent clinical studies involving heart transplant patients. The presentations took place during the 2015 International Society of Heart & Lung Transplant (ISHLT) in Nice, France, April 15–18.
Mayo Clinic physicians presented oral and poster presentations on 16 studies at ISHLT this year. The conference attracts 3,000 health care professionals from 45 countries who represent more than 15 different medical disciplines involved in the management and treatment of end-stage heart and lung disease. A few highlights of the Mayo Clinic-related research include:
“Are psychosocial characteristics predictive of death and rehospitalization after destination left ventricular assist device?”
This study examined psychosocial factors, such as drug use, depression and nonsmoking status to determine if they are associated with higher rehospitalization risk after a patient has received a left ventricular assist device (LVAD).
The study concluded that drug use, depression and nonsmoking status are associated with higher rehospitalization risk after LVAD. These data may be helpful in stratifying and communicating risk to patients who are considering LVAD as destination therapy.
“Sirolimus-based immunosuppression results in lower incidence of post-transplantation lymphoproliferative disorders in heart transplant recipients”
This study examines whether the use of sirolimus-based immunosuppression (SRL) drug therapy affects whether a patient will be diagnosed with a form of cancer that affects transplant patients. Known as post-transplantation lymphoproliferative disorder, this type of malignancy occurs in 2 percent to 9 percent of heart transplant patients.
The study concluded that these initial observations suggest that post-transplantation lymphoproliferative disorders PTLD incidence is lower in heart transplant recipients on sirolimus-based immunosuppression. The mechanism may be due to the powerful anti-proliferative effect of sirolimus. This study highlights another potential advantage of SRL that may improve long-term survival following heart transplantation.
“HVAD insertion via right ventricular interposition: a novel strategy for biventricular support”
This presentation will feature the case of a Mayo patient who received a new implantable ventricular support device that was designed for smaller patients whose chest cavities will not accommodate existing ventricular support devices. With the Hybrid Ventricular Assist Device (HVAD), Mayo physicians were able to support the patient while she awaited heart transplant.
The ISHLT was created in 1981 by a small group of cardiologists and cardiac surgeons who were dedicated to improving the care of patients with advanced heart or lung disease.
About Transplantation at Mayo Clinic Mayo Clinic has one of the nation’s largest and most experienced transplant practices, with campuses in Minnesota, Arizona and Florida. Over 200 doctors in transplant medicine and surgery perform about 1,800 transplants a year, and have a long track record of excellent outcomes. The heart transplant program at Mayo Clinic in Rochester is part of the integrated William J. von Liebig Transplant Center, where more than 800 solid organ and blood and marrow transplants take place every year. The opportunity to collaborate with multiple transplant programs allows Mayo Clinic patients access to a multidisciplinary transplant team and the opportunity for multiorgan transplantation if necessary.